These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 9508789)
1. Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes. He S; Sim RB; Whaley K Mol Med; 1998 Feb; 4(2):119-28. PubMed ID: 9508789 [TBL] [Abstract][Full Text] [Related]
2. Autoantibody facilitated cleavage of C1-inhibitor in autoimmune angioedema. Jackson J; Sim RB; Whaley K; Feighery C J Clin Invest; 1989 Feb; 83(2):698-707. PubMed ID: 2536404 [TBL] [Abstract][Full Text] [Related]
3. Epitope mapping of C1 inhibitor autoantibodies from patients with acquired C1 inhibitor deficiency. He S; Tsang S; North J; Chohan N; Sim RB; Whaley K J Immunol; 1996 Mar; 156(5):2009-13. PubMed ID: 8596057 [TBL] [Abstract][Full Text] [Related]
4. Role of the distal hinge region of C1-inhibitor in the regulation of C1s activity. He S; Yang JC; Tsang S; Sim RB; Whaley K FEBS Lett; 1997 Aug; 412(3):506-10. PubMed ID: 9276455 [TBL] [Abstract][Full Text] [Related]
5. The acquired C1-INH deficiencies with autoantibodies (AAE type II). Alsenz J; Loos M Behring Inst Mitt; 1989 Jul; (84):165-72. PubMed ID: 2679532 [TBL] [Abstract][Full Text] [Related]
6. A secondary C1s interaction site on C1-inhibitor is essential for formation of a stable enzyme-inhibitor complex. He S; Sim RB; Whaley K FEBS Lett; 1997 Mar; 405(1):42-6. PubMed ID: 9094421 [TBL] [Abstract][Full Text] [Related]
7. ELISA to measure neutralizing capacity of anti-C1-inhibitor antibodies in plasma of angioedema patients. Engel R; Rensink I; Roem D; Brouwer M; Kalei A; Perry D; Zeerleder S; Wouters D; Hamann D J Immunol Methods; 2015 Nov; 426():114-9. PubMed ID: 26318839 [TBL] [Abstract][Full Text] [Related]
8. Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1. Chesne S; Villiers CL; Arlaud GJ; Lacroix MB; Colomb MG Biochem J; 1982 Jan; 201(1):61-70. PubMed ID: 6282262 [TBL] [Abstract][Full Text] [Related]
9. In vitro stimulation of C1s proteolytic activities by C1s-presenting autoantibodies from patients with systemic lupus erythematosus. He S; Lin YL J Immunol; 1998 May; 160(9):4641-7. PubMed ID: 9574573 [TBL] [Abstract][Full Text] [Related]
10. Relevance of lymphoproliferative disorders and of anti-C1 inhibitor autoantibodies in acquired angio-oedema. Cicardi M; Beretta A; Colombo M; Gioffré D; Cugno M; Agostoni A Clin Exp Immunol; 1996 Dec; 106(3):475-80. PubMed ID: 8973615 [TBL] [Abstract][Full Text] [Related]
11. C1 inhibitor-C1s complexes are internalized and degraded by the low density lipoprotein receptor-related protein. Storm D; Herz J; Trinder P; Loos M J Biol Chem; 1997 Dec; 272(49):31043-50. PubMed ID: 9388254 [TBL] [Abstract][Full Text] [Related]
12. Structure and function of C1 inhibitor. Davis AE Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529 [TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against Complement Classical Pathway Components C1q, C1r, C1s and C1-Inh in Patients with Lupus Nephritis. Radanova M; Vasilev V; Mihaylova G; Kosturkova M; Kishore U; Roumenina L Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012546 [TBL] [Abstract][Full Text] [Related]
14. Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor. Wijeyewickrema LC; Lameignere E; Hor L; Duncan RC; Shiba T; Travers RJ; Kapopara PR; Lei V; Smith SA; Kim H; Morrissey JH; Pike RN; Conway EM Blood; 2016 Sep; 128(13):1766-76. PubMed ID: 27338096 [TBL] [Abstract][Full Text] [Related]
15. Polyclonal autoantibodies against C1 inhibitor in a case of acquired angioedema. Ponce IM; Caballero T; Reche M; Piteiro AB; López-Serrano MC; Fontán G; López-Trascasa M Ann Allergy Asthma Immunol; 2002 Jun; 88(6):632-7. PubMed ID: 12086372 [TBL] [Abstract][Full Text] [Related]
16. Trimer and tetramer complexes containing C1 esterase inhibitor, C1r and C1s, in serum and synovial fluid of patients with rheumatic disease. Laurell AB; Mårtensson U; Sjöholm AG J Immunol Methods; 1990 May; 129(1):55-61. PubMed ID: 2338498 [TBL] [Abstract][Full Text] [Related]
17. Biosynthesis of complement C1 inhibitor by Hep G2 cells. Reactivity of different glycosylated forms of the inhibitor with C1s. Prandini MH; Reboul A; Colomb MG Biochem J; 1986 Jul; 237(1):93-8. PubMed ID: 3099750 [TBL] [Abstract][Full Text] [Related]
18. Unmasking of acquired autoimmune C1-inhibitor deficiency by an angiotensin-converting enzyme inhibitor. Kleiner GI; Giclas P; Stadtmauer G; Cunningham-Rundles C Ann Allergy Asthma Immunol; 2001 Apr; 86(4):461-4. PubMed ID: 11345293 [TBL] [Abstract][Full Text] [Related]
19. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies. Donaldson VH; Harrison RA; Rosen FS; Bing DH; Kindness G; Canar J; Wagner CJ; Awad S J Clin Invest; 1985 Jan; 75(1):124-32. PubMed ID: 3965500 [TBL] [Abstract][Full Text] [Related]
20. Acquired C1 inhibitor (C1-INH) deficiency type II. Replacement therapy with C1-INH and analysis of patients' C1-INH and anti-C1-INH autoantibodies. Alsenz J; Lambris JD; Bork K; Loos M J Clin Invest; 1989 Jun; 83(6):1794-9. PubMed ID: 2723058 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]